4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by Chard

Chardan Capital began coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report released on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $30.00 price target on the stock. Several other equities research analysts have also recently issued reports on FDMT. SVB Securities lowered their price objective […]

Related Keywords

United States , America , Scott Bizily , Deutsche Bank , Pricet Rowe Associates Inc , York Mellon Corp , Connor Clark Lunn Investment Management Ltd , Securities Exchange Commission , Charles Schwab Investment Management Inc , D Molecular Therapeutics Inc , Chardan Capital , Molecular Therapeutics , Free Report , Moderate Buy , Global Investors Lp Viking , Exchange Commission , Lunn Investment Management , New York Mellon Corp , Schwab Investment Management , Molecular Therapeutics Daily ,